You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 3, 2024

Claims for Patent: 10,500,247

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,500,247

Title:	Method of treating low blood pressure
Abstract:	A method for treating a patient suffering from one of septic shock, acute kidney injury, severe hypotension, cardiac arrest, and refractory hypotension, but not from myocardial infarction, is provided. The method includes administering a therapeutically effective dose of Angiotensin II, or Ang II, to the patient.
Inventor(s):	Chawla; Lakhmir (McLean, VA)
Assignee:	The George Washington University a Congressionally Chartered Not-for-Profit Corporation (Washington, DC)
Application Number:	15/870,139
Patent Claims:	1. A method of treating low blood pressure in a human patient suffering from acute kidney injury, refractory hypotension or severe hypotension, comprising administering angiotensin II to the patient at an initial rate from about 5 ng/kg/min to about 20 ng/kg/min. 2. The method of claim 1, wherein the initial rate is about 5 ng/kg/min. 3. The method of claim 1, wherein the initial rate is about 10 ng/kg/min. 4. The method of claim 1, wherein the initial rate is about 20 ng/kg/min. 5. The method of claim 1, wherein the initial rate is from about 10 ng/kg/min to about 20 ng/kg/min. 6. The method of claim 1, wherein the method further comprises titrating the rate up. 7. The method of claim 6, wherein the dose is titrated up to about 30 ng/kg/min. 8. The method of claim 6, wherein the dose is titrated up to about 40 ng/kg/min. 9. The method of claim 1, wherein the angiotensin II is administered to the patient over a period of about 0.25 hours to about 120 hours. 10. A method of treating low blood pressure in a human patient suffering from acute kidney injury, refractory hypotension or severe hypotension, comprising administering angiotensin II to the patient at an initial rate from about 5 ng/kg/min to about 20 ng/kg/min; wherein the method further comprises titrating the rate up, and wherein the angiotensin II is administered to the patient over a period of about 0.25 hours to about 120 hours. 11. The method of claim 10, wherein the initial rate is about 5 ng/kg/min. 12. The method of claim 10, wherein the initial rate is about 10 ng/kg/min. 13. The method of claim 10, wherein the initial rate is about 20 ng/kg/min. 14. The method of claim 10, wherein the initial rate is from about 10 ng/kg/min to about 20 ng/kg/min. 15. The method of claim 10, wherein the dose is titrated up to about 30 ng/kg/min. 16. The method of claim 10, wherein the dose is titrated up to about 40 ng/kg/min. 17. The method of claim 1, wherein the angiotensin II is human angiotensin II. 18. The method of claim 10, wherein the angiotensin II is human angiotensin II. 19. The method of claim 5, wherein the method further comprises titrating the rate up. 20. The method of claim 19, wherein the dose is titrated up to about 30 ng/kg/min. 21. The method of claim 19, wherein the dose is titrated up to about 40 ng/kg/min. 22. The method of claim 5, wherein the angiotensin II is administered to the patient over a period of about 0.25 hours to about 120 hours.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.